{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005499","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.988426+00:00","generated_at":"2026-05-16T11:26:28.703422+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Rapport Therapeutics registers up to $110M in at-the-market stock offering","bullets":["Filed prospectus supplement on Jan 7, 2026 to sell up to $110M of common stock through Leerink and Cantor Fitzgerald.","Sales would be made under existing Sales Agreement dated July 1, 2025; no sales have occurred to date.","Legal opinion from Goodwin Procter LLP filed as Exhibit 5.1.","Offering is for general corporate purposes; no specific use of proceeds disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005499","json":"https://secwatch.observer/filing/0001193125-26-005499.json","markdown":"https://secwatch.observer/filing/0001193125-26-005499.md","text":"https://secwatch.observer/filing/0001193125-26-005499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526005499/0001193125-26-005499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526005499/rapp-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:26:28.703422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}